English 中文简体 中文繁体
PIPELINE OVERVIEW

Leveraging its proprietary technology platforms, Alphamab Oncology has developed an exciting portfolio of pipeline programs with clear differentiation and global competitiveness. With clinically proven targets, CMC-validated manufacturing and global IP rights, Alphamab Oncology has created a well-rounded pipeline with lower risk and superb upside potential.


Recent progress in cancer immunotherapy has marked a historic breakthrough in cancer treatment. At Alphamab Oncology, we have developed not only a well differentiated PD-L1 antibody (KN035), but also a potential backbone of next-generation immuno-oncology therapy (KN046), representing a leap forward from currently available drugs on the market or in development.


Several other bispecific programs with best-in-class or first-in-class potential are also under development at the company.

Pipeline Programs